Skip to main content

Prader-Willi Syndrome clinical trials at UC Health
4 in progress, 2 open to eligible people

  • A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

    open to eligible people ages 4 years and up

    The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.

    at UC Irvine

  • Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome

    open to eligible people ages 8-17

    The primary objective of this study is to assess the efficacy of Cannabidiol Oral Solution on hyperphagia-related behavior in subjects with Prader-Willi Syndrome (PWS). The secondary objectives of this study are to assess the efficacy, safety and tolerability, impact on quality of life, and impact on physical activity of Cannabidiol Oral Solution in subjects with PWS.

    at UCSD

  • Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

    Sorry, not currently recruiting here

    This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).

    at UC Irvine

  • SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

    Sorry, in progress, not accepting new patients

    This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care. The primary objective is to evaluate the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 microdeletion (DiGeorge syndrome) in this large cohort of pregnant women. This will be done by performing a review of perinatal medical records and obtaining biospecimens after birth to perform genetic diagnostic testing for 22q11.2 deletion. Results from the follow-up specimens will be compared to those obtained by the Panorama screening test to determine test performance. Specific test performance parameters will include: PPV, specificity, and sensitivity.

    at UCSF

Last updated: